Amarin Corp

AMRN

Market cap $305M

DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece.

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMRN beats earnings and sales estimates as Vascepa sales rise and cost cuts take hold, while the partnered Europe strategy reshapes growth.

Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026).

Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

Amarin has one drug, and it has lost key patent protections. The company is cutting costs in an effort to generate positive cash flow.

Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.